Whalesbook
Sanofi India Limited is set to hold its 70th Annual General Meeting (AGM) on Wednesday, April 29, 2026, at 3:30 p.m. IST via video conference. Shareholders will vote on several key proposals, including the appointment of three new directors, approval for substantial related party transactions (RPTs) totaling ₹1,915 crore, and the declaration of a ₹123 per share dividend for the fiscal year 2025.
The meeting's agenda includes bringing new expertise to the board with the proposed appointment of Ms. Sudipta Chakraborty as Director and Whole-time Director. Additionally, Mrs. Rajani Kesari and Mr. Siraj Azmat Chaudhry are proposed as Independent Directors, aiming to strengthen governance and strategic oversight.
A significant item for shareholder approval involves material related party transactions (RPTs) crucial for upcoming operations. The company seeks approval for transactions up to ₹1,385 crore with Sanofi-Aventis Singapore Pte. Limited and up to ₹530 crore with Sanofi Healthcare India Private Limited for the Financial Year 2026. These deals are vital for maintaining operational continuity and leveraging group synergies.
Shareholders will also vote on adopting the company's audited financial statements for the year ended December 31, 2025. Alongside this, the company proposes declaring a total dividend of ₹123 per equity share for FY2025. This distribution comprises an interim dividend of ₹75 per share and a recommended final dividend of ₹48 per share.
The approval of these RPTs is a routine but important part of Sanofi India's operations, allowing it to engage in necessary transactions with affiliated companies to support its supply chain and business activities. Historically, Sanofi India has had similar agreements, including prior approvals for transactions with Sanofi-Aventis Singapore Pte. Ltd. and Sanofi Healthcare India Private Limited.
Sanofi India's commitment to governance and compliance is also underscored by past regulatory matters. The company faced a ₹3 crore penalty from the Competition Commission of India (CCI) in 2015 for unfair trade practices. Furthermore, in 2018, Sanofi settled with the US SEC for $25.2 million concerning Foreign Corrupt Practices Act (FCPA) violations. These past events highlight the importance of strict adherence to compliance and ethical conduct, especially when approving significant transactions.
Investors will be closely watching the outcome of the shareholder votes on director appointments and the proposed RPTs. The decisions made at this AGM will shape the board's composition and approve critical financial dealings that support Sanofi India's operations for the upcoming fiscal year.